Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Major Depression, Schizophrenia, Bipolar Disorder
About this trial
This is an interventional health services research trial for Major Depression focused on measuring Major depression and Cancer, Schizophrenia and Cancer, Bipolar disorder and Cancer, Lung Cancer, Breast Cancer, Head and Neck cancer, GI cancer, Schizophrenia, Bipolar disorder
Eligibility Criteria
Inclusion Criteria:
- Individuals with a diagnosis of a primary psychotic disorder (schizophrenia, schizoaffective disorder, delusional disorder), bipolar disorder, or major depressive disorder with prior psychiatric hospitalization, confirmed by diagnostic assessment of the PI, a psychiatrist with expertise in SMI and cancer
- Within 8 weeks of initial oncology consultation at the MGH Cancer Center (patients who come for a second opinion and opt to have their cancer treatment at MGH will be considered eligible, patients who have been treated previously for other types of cancer will be considered eligible).
- Age >18 years old, verbal fluency in English
- Suspected or newly diagnosed lung, GI, head/neck, or breast cancer documented in initial oncology note or confirmed by pathology
Exclusion Criteria:
- Cognitive impairment severe enough to interfere with completing the study assessments or providing informed consent
- History of dementia or traumatic brain injury
- Refuse participation
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Experimental
Proactive Psychiatry Consultation (PPC)
The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention. Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline) Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)